- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Announces $130 Million Private Placement Financing
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
- Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
- Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Friday, Acrivon Therapeutics Inc (ACRV:NMQ) closed at 9.39, -34.34% below its 52-week high of 14.30, set on May 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.24 |
---|---|
High | 10.77 |
Low | 9.10 |
Bid | 9.15 |
Offer | 11.66 |
Previous close | 10.54 |
Average volume | 4.21m |
---|---|
Shares outstanding | 30.87m |
Free float | 20.09m |
P/E (TTM) | -- |
Market cap | 325.39m USD |
EPS (TTM) | -2.73 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼